$2.92
$6.75
52-Week Range
At a Glance
AI-generated8-K
Pluri Inc. entered into a Securities Purchase Agreement with Chutzpah Holdings LP on March 25, 2026, for a private placement offering of 625,000 common shares and warrants to purchase 625,000 common shares at a combined price of $4.00 per unit, generating expected gross proceeds of approximately $2.5 million for working capital and general corporate purposes.$27M
Market Cap
$1M
Revenue
-$23M
Net Income
Employees106
Fundamentals
How The Business Makes Money
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Industry Biotechnology
Activity
What Changed Recently
Company Profile
CIK0001158780
ISINUS72942G2030
CUSIP72942G104
Phone972 7 4710 8600
AddressBuilding No. 5, Haifa, 3508409, IL
SEC EDGAR